Claims for Patent: 5,169,849

Summary for Patent: 5,169,849

Title:	Nasal pharmaceutical compositions
Abstract:	A nasal pharmaceutical composition incorporates a non-toxic agent which is capable of increasing the ciliary function e.g. caffeine and at least partially antagonizing the ciliary function depressant effect of the active agent e.g. dihydroergotamine or any other constituent present in the composition.
Inventor(s):	Kiechel; Jean-Rene (Rueil-Malmaison, FR), Acezat-Mispelter; Francoise (Elancourt, FR), Plas; Danielle (Rueil-Malmaison, FR)
Assignee:	Sandoz Ltd. (Basel, CH)
Application Number:	07/603,990
Patent Claims:	1. A liquid nasal pharmaceutical composition containing as an active agent a pharmaceutically effective amount of dihydroergotamine which is capable of depressing the ciliary function and an effective amount of a xanthine which is capable of increasing the ciliary function, wherein the weight ratio of said dihydroergotamine to said xanthine is about from 0.1:1 to 10:1. 2. A composition according to claim 1 wherein the dihydroergotamine present is in the form of the mesylate. 3. A composition according to claim 1 wherein the xanthine is of formula ##STR2## wherein R.sub.1, R.sub.1 and R.sub.3 are chosen from hydrogen or alkyl (C.sub.1-10). 4. A composition according to claim 3 wherein the xanthine is theophylline. 5. A composition according to claim 3 wherein the xanthine is caffeine. 6. A composition according to claim 5 containing a non-toxic isotonizing agent. 7. A composition according to claim 6 wherein the weight ratio of agent capable of increasing the ciliary function to isotonizing agent is from 1:0.05 to 1:10. 8. A composition according to claim 6 wherein the isotonizing agent is a sugar. 9. A composition according to claim 8 wherein the sugar is glucose. 10. A composition according to claim 9 wherein the weight ratio of ciliary function increasing agent to glucose is from 1:1 to 1:10. 11. A composition according to claim 1 in the form of a solution. 12. A composition according to claim 1 wherein the osmotic pressure is from 280 to 360 mOsm per liter. 13. A composition according to claim 1 in unit dosage form saturated with carbon dioxide gas. 14. A composition according to claim 1 in a nasal spray applicator. 15. A composition according to claim 14 wherein the spray applicator is designed to produce a spray of droplet size 800 to 1000 microns in diameter. 16. A nasal pharmaceutical composition comprising dihydroergotamine mesylate and caffeine in a weight ratio of 1:0.1 to 1:1 and glucose. 17. A method of nasally systemically administering a pharmaceutically effective amount of dihydroergotamine which is capable of depressing the ciliary function comprising nasally co-administering an effective amount of a xanthine which is capable of increasing ciliary function, wherein the weight ratio of said dihydroergotamine to said xanthine is about from 0.1:1 to 10:1. 18. A method according to claim 17 of treating hypotension or migraine. 19. A method of claim 17 wherein the dihydroergotamine is in the form of the mesylate. 20. A method of claim 17 wherein the xanthine is of formula ##STR3## wherein R.sub.1, R.sub.1 and R.sub.3 are chosen from hydrogen or alkyl(C.sub.1-10). 21. A method of claim 20 wherein the xanthine is theophylline. 22. A method of claim 20 wherein the xanthine is caffeine. 23. A method of claim 20 wherein from 2 to 20 mg of xanthine per dose is administered. 24. A method according to claim 17 wherein a spray of liquid is administered. 25. A method according to claim 24 wherein the osmotic pressure of the liquid is 280 to 360 mOsm per liter. 26. A method according to claim 17 wherein a spray of powder is administered. 27. A method according to any one of claims 17 wherein a non-toxic isotonizing agent is also co-administered. 28. A method according to claim 27 wherein the isotonizing agent is a sugar. 29. A method according to claim 28 wherein the sugar is glucose. 30. A method according to claim 29 wherein the dose of sugar is from about 10 to 100 mg. 31. A method according to any one of claims 17 wherein the dose of dihydroergotamine administered is from 0.5 to 5 mg.